REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 4, 2012--
Codexis, Inc. (NASDAQ: CDXS), a developer of cost-advantaged processes
for the production of biofuels, bio-based chemicals and pharmaceuticals,
today announced the appointment of David O’Toole as Senior Vice
President and Chief Financial Officer, effective September 4, 2012.
David O’Toole served most recently as Vice President and Chief Financial
Officer at Response Genetics, Inc. (NASDAQ: RGDX), a company focused on
the development and sale of molecular diagnostic tests for cancer and
analytical testing services of clinical trial specimens for the
pharmaceutical industry. In this role, David managed the finance and
accounting department and was responsible for investor relations and
information technologies. During David’s time at Response Genetics, he
implemented policies and procedures across all company functions that
resulted in significant cost savings and operational efficiencies for
the business. David also successfully completed a number of equity
From 2008 to 2009, David was Executive Vice President and Chief
Financial Officer of Abraxis Bioscience, Inc., a publicly traded global
biotechnology company with a market capitalization of approximately $3
billion. As CFO, David managed a department of 40 people and
successfully implemented the company’s first Sarbanes Oxley 404
compliance cycle, a robust financial planning and analysis program and a
new ERP system. David also helped establish operations and successfully
launch commercial activities in Europe and China.
Prior to Abraxis, David spent sixteen years with the accounting firm of
Deloitte & Touche LLP, including twelve years as a partner, where he
provided international business, operational and tax advice to medium
and large multinational companies His time with Deloitte also included
two years in Paris, France. David’s practice focused on life science and
biotechnology companies during his last eight years at Deloitte. He led
a large team of cross functional partners and managers providing
consulting services to life science companies. These services included
Sarbanes Oxley compliance, revenue cycle management, supply chain
management, real estate services, ERP implementation and finance,
accounting and tax services.
“David brings to Codexis a wealth of financial experience in the life
sciences sector. His experience organizing and managing finance,
accounting and investor relations departments and developing and
executing corporate strategy will be important as we continue to refine
our strategy for controlling our balance sheet and generating
differentiated commercial products in the biofuels, bio-based chemicals
and pharmaceuticals markets,” said John Nicols, President and CEO of
Codexis. “He is the right CFO at the right time for this company.”
“I am excited to join the great team at Codexis, and to help strengthen
the company’s pharmaceutical business and continue its transformation
into a world-scale commercial entity in biofuels and bio-based
chemicals,” said David O’Toole. “Codexis has tremendous assets and I
look forward to helping the company realize its full potential.”
Biographical Information for David O’Toole
David O’Toole has over 25 years of experience in the accounting and
finance sectors, and for the past twelve years has focused on the life
science and biotech industry. From May 2010 to August 2012, David was
Vice President and Chief Financial Officer at Response Genetics, Inc.
(NASDAQ: RGDX), a company focused on the development and sale of
molecular diagnostic tests for cancer and analytical testing services of
clinical trial specimens for the pharmaceutical industry. From 2008 to
2009, David was Executive Vice President and Chief Financial Officer of
Abraxis Bioscience, Inc., a global, publicly traded biotechnology
company that was later acquired by Celgene Corporation (NASDAQ: CELG).
From 1992 to 2008, David worked at Deloitte & Touche LLP where he served
for twelve years as a partner, providing international business,
operational and tax advice to medium and large multinational companies,
including many in the life science and biotech sector. From 1984 to
1992, he worked at Arthur Anderson & Co. as an international tax
manager, spending two of those years in Tokyo, Japan. David received his
Bachelor of Science, Accounting from the University of Arizona and is a
certified public accountant.
About Codexis, Inc.
Codexis, Inc. is a developer of cost-advantaged processes for the
production of biofuels, bio-based chemicals and pharmaceuticals.
Codexis’ product lines include CodeXyme™ cellulase enzymes and CodeXol™
detergent alcohol. Partners and customers include global leaders such as
Merck, Pfizer and Teva. For more information, see www.codexis.com.
Codexis Forward-Looking Statements
This press release contains forward-looking statements relating to
Codexis’ efforts to control its balance sheet and to generate
differentiated commercial products in the biofuels, bio-based chemicals
and pharmaceuticals markets, to strengthen Codexis’ pharmaceutical
business, and to transform itself into a world-scale commercial entity
in biofuels and bio-based chemicals. You should not place undue reliance
on these forward-looking statements because they involve known and
unknown risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual results.
Factors that could materially affect actual results include Codexis’
need for substantial additional capital in the future in order to
execute on its strategy; Codexis’ dependence on its collaborators; the
market's reception to Codexis’ and its customers' pharmaceutical
products; the need for regulatory approval of Codexis’ customers'
manufacturing processes and products; Codexis' ability to develop and
commercialize new products for the pharmaceutical market; Codexis'
ability to maintain license rights to a commercial scale expression
system for enzymes that convert cellulosic biomass to sugars; the
availability, cost or location of renewable feedstocks used by Codexis’
potential customers; fluctuations in the price of and demand for certain
commodities using Codexis’ technology; Codexis' limited experience in
developing, manufacturing, marketing, selling and distributing
commercial cellulase enzymes; various challenges to the feasibility of
the production and commercialization of biofuels and bio-based chemicals
derived from cellulose; the impact of Codexis’ workforce reduction and
restructuring efforts on the operation of the Company’s business; the
possibility that Codexis may need to undertake additional restructuring
efforts as a result of the loss of ongoing funding from Shell; and
Codexis’ need to retain key employees. Additional factors that could
materially affect actual results can be found in Codexis’ Quarterly
Report on Form 10-Q for the period ended June 30, 2012 filed with the
Securities and Exchange Commission on August 9, 2012, including under
the caption “Risk Factors.” Codexis expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.
Source: Codexis, Inc.
Paul Cox, 212-362-1200